Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-039 in Relapsed/Refractory or Metastatic Solid Tumors
NCT04794972Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Apr 2021
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs), T-cell Engagers, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GNC-039 in glioma and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 14 days, Maximum Tolerated Dose at 14 days and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
GNC-039
03
Conditions
gliomasolid tumor
Beyond the preview
Go deeper on NCT04794972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04794972.